They haven't gone silent, they've just released the report and confirmed their commercialisation strategy! Which, for clarity, is centered around cardio protection with anti-cancer synergy, and the sales pipeline has been estimated based on synergies with anthracyclines.
We know there are data being held for legitimate IP protection reasons. And we know that negative results don't drive that action.
Breast cancer trial getting underway.
I can't explain the lack of interest but I can point to the fact that until it's a competitive field, they can try to develop their own and play "wait and see". And I can point to plenty of other forums who think we (RAC investors) are crazy, I'm betting they're wrong.
Ann: Race releases complete cardio-protection data & video, page-95
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.020(1.31%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.57 | $1.55 | $1.987K | 1.274K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6040 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1462 | 2 |
View Market Depth
| Last trade - 10.53am 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |